12-Nov-2025 3:01 PM CST - Business Wire AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2025. This quarter, we continued to execute across a diverse pipeline spanning multiple, potentially high impact projects in infectious diseases and oncology, leveraging our boron chemistry platform to ad
6-Nov-2025 4:03 PM CST - Business Wire AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference being held from December 2-4, 2025. Details of the event are as follows: Eric Easom, Co-Founder, Chairman, President and
12-Aug-2025 3:01 PM CST - Business Wire AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2025. We saw continued momentum this quarter across our boron chemistry pipeline as we look to develop high-impact drugs that address serious and overlooked conditions. In our Chagas disease program, we recen
13-May-2025 3:01 PM CST - Business Wire AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025. As we look ahead to the remainder of 2025, we are poised to advance our pipeline leveraging our boron chemistry platform, which has the potential to address serious unmet needs of patients. We have high
30-Apr-2025 6:00 AM CST - Business Wire AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event is as follows: Citizens JMP Life Sciences Conference Eric
25-Mar-2025 3:00 PM CST - Business Wire AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024. "Epetraborole demonstrated potential proof-of-concept in Phase 2, achieving nominal statistical significance on two patient-reported outcome measures in patients with treatment-refractory MA
3-Mar-2025 3:00 PM CST - Business Wire AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, wil
20-Feb-2025 6:00 AM CST - Business Wire AN2 Therapeutics to Participate at Upcoming Investor Conferences AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monda
29-Jan-2025 3:00 PM CST - Business Wire AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Fou
12-Nov-2025 3:01 PM CST - Business Wire AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2025. This quarter, we continued to execute across a diverse pipeline spanning multiple, potentially high impact projects in infectious diseases and oncology, leveraging our boron chemistry platform to ad
6-Nov-2025 4:03 PM CST - Business Wire AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference being held from December 2-4, 2025. Details of the event are as follows: Eric Easom, Co-Founder, Chairman, President and
12-Aug-2025 3:01 PM CST - Business Wire AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2025. We saw continued momentum this quarter across our boron chemistry pipeline as we look to develop high-impact drugs that address serious and overlooked conditions. In our Chagas disease program, we recen
13-May-2025 3:01 PM CST - Business Wire AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2025. As we look ahead to the remainder of 2025, we are poised to advance our pipeline leveraging our boron chemistry platform, which has the potential to address serious unmet needs of patients. We have high
30-Apr-2025 6:00 AM CST - Business Wire AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event is as follows: Citizens JMP Life Sciences Conference Eric
25-Mar-2025 3:00 PM CST - Business Wire AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2024. "Epetraborole demonstrated potential proof-of-concept in Phase 2, achieving nominal statistical significance on two patient-reported outcome measures in patients with treatment-refractory MA
3-Mar-2025 3:00 PM CST - Business Wire AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, wil
20-Feb-2025 6:00 AM CST - Business Wire AN2 Therapeutics to Participate at Upcoming Investor Conferences AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monda
29-Jan-2025 3:00 PM CST - Business Wire AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Details of the event are as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual) Eric Easom, Co-Fou
